Tag Archives: CTMX

CytomX Therapeutics (CTMX) Gets a Buy Rating from Nomura

In a report issued on May 14, Christopher Marai from Nomura maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $9.01. According to TipRanks.com, Marai

H.C. Wainwright Keeps Their Buy Rating on CytomX Therapeutics (CTMX)

In a report released today, Robert Burns from H.C. Wainwright maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report), with a price target of $12.00. The company’s shares closed last Wednesday at $14.44, close to its 52-week high

Nomura Believes CytomX Therapeutics (NASDAQ: CTMX) Still Has Room to Grow

In a report issued on May 8, Christopher Marai from Nomura maintained a Buy rating on CytomX Therapeutics (CTMX – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $14.24, close to its 52-week

Analysts Are Bullish on These Healthcare Stocks: CytomX Therapeutics (CTMX), Stoke Therapeutics (STOK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CytomX Therapeutics (CTMX – Research Report) and Stoke Therapeutics (STOK – Research Report) with bullish sentiments. CytomX Therapeutics (CTMX) Mizuho Securities analyst

CytomX Therapeutics (CTMX) Received its Third Buy in a Row

After Mizuho Securities and Cowen & Co. gave CytomX Therapeutics (NASDAQ: CTMX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Robert Burns reiterated a Buy rating on CytomX Therapeutics today and set

H.C. Wainwright Reiterates Their Buy Rating on CytomX Therapeutics (CTMX)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a price target of $14.00. The company’s shares closed last Monday at $7.34, close to its 52-week low of $5.10. According